We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-18.21%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$12.2B
AUM Growth
-$2.97B
Cap. Flow
+$24.4M
Cap. Flow %
0.2%
Top 10 Hldgs %
86.1%
Holding
101
New
4
Increased
12
Reduced
21
Closed
10

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$219M
2
AMRN
Amarin Corp
AMRN
+$155M
3
KOD icon
Kodiak Sciences
KOD
+$81M
4
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$22.3M
5
KRYS icon
Krystal Biotech
KRYS
+$14M

Top Sells

Rank Stock Value
1
GHDX
Genomic Health, Inc.
GHDX
+$143M
2
SAGE
Sage Therapeutics
SAGE
+$80.2M
3
NVTA
Invitae Corporation
NVTA
+$58.3M
4
ECYT
Endocyte, Inc. Common Stock
ECYT
+$45.3M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$21.5M

Sector Composition

Rank Sector Weight
1 Healthcare 92.2%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBAY
26
DELISTED
Cymabay Therapeutics
CBAY
$38.7M 0.32%
4,917,700
– –
TCDA
27
DELISTED
Tricida, Inc. Common Stock
TCDA
$37.7M 0.31%
1,600,000
– –
DBVT
28
DBV Technologies
DBVT
$817M
$35.4M 0.29%
550,956
– –
ZYME icon
29
Zymeworks
ZYME
$1.62B
$25.1M 0.21%
1,708,472
+397,387
+30% +$5.21M
INSM icon
30
Insmed
INSM
$22.3B
$24.3M 0.2%
1,851,982
– –
NGNE icon
31
Neurogene
NGNE
$672M
$23.6M 0.19%
546,708
– –
BOLD
32
DELISTED
Audentes Therapeutics, Inc
BOLD
$19.4M 0.16%
910,463
+517,241
+132% +$13.3M
QURE icon
33
uniQure
QURE
$2.75B
$17.4M 0.14%
605,000
– –
KRYS icon
34
Krystal Biotech
KRYS
$10.7B
$16.3M 0.13%
784,674
+670,000
+584% +$14M
MRUS
35
DELISTED
Merus
MRUS
$16.2M 0.13%
1,160,014
– –
AIMT
36
DELISTED
Aimmune Therapeutics
AIMT
$16.1M 0.13%
673,908
– –
XNCR icon
37
Xencor
XNCR
$1.45B
$15.9M 0.13%
440,186
-162,309
-27% -$5.96M
SLDB icon
38
Solid Biosciences
SLDB
$791M
$15.8M 0.13%
39,192
– –
MYOK
39
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$15.4M 0.13%
315,243
-41,972
-12% -$2.31M
ABEO icon
40
Abeona Therapeutics
ABEO
$356M
$15M 0.12%
84,127
-3,248
-4% -$708K
RARX
41
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$15M 0.12%
823,113
+645,161
+363% +$10.1M
ACGN
42
DELISTED
Aceragen Inc
ACGN
$13.4M 0.11%
284,769
+138
+0% +$15.9K
SYRE icon
43
Spyre Therapeutics
SYRE
$8.5B
$12.8M 0.11%
68,544
+13,029
+23% +$2.76M
SGMO
44
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$11.5M 0.09%
999,823
-284,100
-22% -$3.53M
CFRX
45
DELISTED
ContraFect Corporation
CFRX
$10.9M 0.09%
8,941
– –
NVAX icon
46
Novavax
NVAX
$1.21B
$8.68M 0.07%
235,916
– –
MRKR icon
47
Marker Therapeutics
MRKR
$18.8M
$8.32M 0.07%
+150,000
New +$10.9M
BLCM
48
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$7.82M 0.06%
267,782
– –
ANAB icon
49
AnaptysBio
ANAB
$1.55B
$7.21M 0.06%
113,086
– –
IFRX icon
50
InflaRx
IFRX
$243M
$6.51M 0.05%
178,987
– –
1
2
3 4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2018 Portfolio in Review

As of Q4 2018, Baker Bros. Advisors held 101 positions worth $12.2B, down 20% from $15.2B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Baker Bros. Advisors's Q4 2018 filing shows 4 new, 12 increased, 21 reduced and 10 closed positions. Its largest new stake was Kodiak Sciences: 9,145,115 shares worth $64.9M. The largest sale was Genomic Health, Inc., an estimated $143M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 91% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q4 2018 buy was Kodiak Sciences: 9,145,115 shares worth $64.9M.
  • Baker Bros. Advisors added most to Acadia Pharmaceuticals in Q4 2018, an estimated $219M increase.
  • Baker Bros. Advisors's biggest Q4 2018 reduction was Genomic Health, Inc., cutting an estimated $143M.
  • Baker Bros. Advisors fully exited Sage Therapeutics in Q4 2018, selling an estimated $80.2M.
  • Baker Bros. Advisors's ten largest holdings make up 86% of its $12.2B portfolio in Q4 2018.
  • Baker Bros. Advisors opened 4 new positions and closed 10 in Q4 2018.
  • Baker Bros. Advisors's portfolio value fell 20% quarter-over-quarter to $12.2B.

Based on Baker Bros. Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.